 |
 |
Perry and list, The cost analysis figures for Parkinson's disease is a much needed study of the significance of the financial burden on not only pwp, but also their families. Society's cost by losing the productive years of pwp who may be stricken with the disease in prime earnings time of their lives and when the pwp could be doing their best for the companies and agencies for whom they work is also significant. I'm pleased that AHRQ has chosen to study Diagnosis and Management of Parkinson's Disease. What or who is MetaWorks, Boston, MA? Jeanette Fuhr 50/47/44? ---------- From: Perry Cohen <[log in to unmask]> To: [log in to unmask] Subject: AHRQ Evidence Practice Centers Examining Parkinson’s Disease Date: Friday, October 27, 2000 7:59 AM The Agency for Healthcare Research and Quality (AHRQ) today announced 15 new research topics for AHRQ’s Evidence-based Practice Centers (EPCs). The EPCs will conduct rigorous, comprehensive reviews of the relevant scientific literature on these topics, including meta-analyses and cost analyses, if appropriate. AHRQ publishes its findings as evidence reports or technology assessments, which are available to the public, health care community, and researchers. "These topics represent the array of questions and challenges facing health care professionals and patients today," said Dr. John M. Eisenberg, Director of AHRQ. "In addition, these reports will enhance our ability to measure and improve the quality and outcomes of health care services." Eleven topics, assigned to EPCs, were nominated by outside organizations: Diagnosis and Management of Parkinson’s Disease. MetaWorks, Boston, MA. Nominated by the American Academy of Neurology. <A HREF="http://www.ahrq.gov/news/press/pr2000/epctop00.htm"> http://www.ahrq.gov/news/press/pr2000/epctop00.htm</A> ******** This research will help us in our efforts to promote access to quality care for all PWP. Perry Cohen Washington DC ----------